The Molecular Basis and Therapeutic Aspects of Cisplatin Resistance in Oral Squamous Cell Carcinoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Nov 8

PMID 34746001

Citations 31

Authors

Yali Cheng

Shaoming Li

Ling Gao

Keqian Zhi

Wenhao Ren

Affiliations

Soon will be listed here.

Abstract

Oral squamous cell carcinoma (OSCC) is a kind of malignant tumors with low survival rate and prone to have early metastasis and recurrence. Cisplatin is an alkylating agent which induces DNA damage through the formation of cisplatin-DNA adducts, leading to cell cycle arrest and apoptosis. In the management of advanced OSCC, cisplatin-based chemotherapy or chemoradiotherapy has been considered as the first-line treatment. Unfortunately, only a portion of OSCC patients can benefit from cisplatin treatment, both inherent resistance and acquired resistance greatly limit the efficacy of cisplatin and even cause treatment failure. Herein, this review outline the underlying mechanisms of cisplatin resistance in OSCC from the aspects of DNA damage and repair, epigenetic regulation, transport processes, programmed cell death and tumor microenvironment. In addition, this review summarizes the strategies applicable to overcome cisplatin resistance, which can provide new ideas to improve the clinical therapeutic outcome of OSCC.

Citing Articles

A Narrative Review of Prognostic Gene Signatures in Oral Squamous Cell Carcinoma Using LASSO Cox Regression.

Mohd Faizal N, Shai S, Savaliya B, Karen-Ng L, Kumari R, Kumar R Biomedicines. 2025; 13(1).

PMID: 39857718 PMC: 11759772. DOI: 10.3390/biomedicines13010134.

miR-128-3p suppresses tumor growth and enhances chemosensitivity in tongue squamous cell carcinoma through MAP2K7 targeting.

Gupta P, Mallick B Mol Biol Rep. 2024; 51(1):1107.

PMID: 39476205 DOI: 10.1007/s11033-024-10040-7.

Resistance to the platinum‑based chemotherapeutic drugs in oral cancer: Focus on the role of p22phox (Review).

Lee J, Wu C, Duh T, Chiu T, Chiu C, Lee C Biomed Rep. 2024; 21(6):182.

PMID: 39420922 PMC: 11484178. DOI: 10.3892/br.2024.1870.

Adjunctive Impact of Mitochondria-Targeting Antibiotics for Cancer Stem Cells of Oral Squamous Cell Carcinoma: Proposal for a Novel Approach in Resistant Cases.

Amiri M, Abbasi H, Hamedani S, Daneste H J Dent (Shiraz). 2024; 25(3):190-191.

PMID: 39371952 PMC: 11452599. DOI: 10.30476/dentjods.2024.102852.2397.

Anticancer Potential of Quercetin on Oral Squamous Cell Carcinoma: A Scoping Review and Molecular Docking.

Afriza D, Arma U, Faslah R, Suriyah W Eur J Dent. 2024; 19(1):15-23.

PMID: 39348855 PMC: 11750326. DOI: 10.1055/s-0044-1789016.

References

Pradere J, Dapito D, Schwabe R . The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2013; 33(27):3485-95. PMC: 4059777. DOI: 10.1038/onc.2013.302. View

Lin J, Lin Y, Fan L, Kuang W, Zheng L, Wu J . miR-203 inhibits cell proliferation and promotes cisplatin induced cell death in tongue squamous cancer. Biochem Biophys Res Commun. 2016; 473(2):382-7. DOI: 10.1016/j.bbrc.2016.02.105. View

Jing Y, Dai J, Chalmers-Redman R, Tatton W, Waxman S . Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999; 94(6):2102-11. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Temam S, Flahault A, Perie S, Monceaux G, Coulet F, Callard P . p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 2000; 18(2):385-94. DOI: 10.1200/JCO.2000.18.2.385. View

Rohwer N, Cramer T . Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat. 2011; 14(3):191-201. DOI: 10.1016/j.drup.2011.03.001. View

Li W, Jie Z, Li Z, Liu Y, Gan Q, Mao Y . ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines. Mol Med Rep. 2014; 9(6):2423-8. DOI: 10.3892/mmr.2014.2112. View

Hsu D, Lan H, Huang C, Tai S, Chang S, Tsai T . Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010; 16(18):4561-71. DOI: 10.1158/1078-0432.CCR-10-0593. View

Forsythe J, Jiang B, Iyer N, Agani F, Leung S, Koos R . Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996; 16(9):4604-13. PMC: 231459. DOI: 10.1128/MCB.16.9.4604. View

10.

Wang Y, Li Q, Xu L, Chen J, Pu Y, Wang L . Cancer stemness of CD10-positive cells regulated by Hedgehog pathway promotes the resistance to cisplatin in oral squamous cell carcinoma. Oral Dis. 2020; 27(6):1403-1411. DOI: 10.1111/odi.13673. View

11.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

12.

Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T . The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer. 2006; 120(2):268-77. DOI: 10.1002/ijc.22294. View

13.

Levine B, Kroemer G . Biological Functions of Autophagy Genes: A Disease Perspective. Cell. 2019; 176(1-2):11-42. PMC: 6347410. DOI: 10.1016/j.cell.2018.09.048. View

14.

Kashani B, Zandi Z, Karimzadeh M, Bashash D, Nasrollahzadeh A, Ghaffari S . Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers. Immunol Res. 2020; 67(6):505-516. DOI: 10.1007/s12026-019-09113-8. View

15.

Sancho-Martinez S, Prieto-Garcia L, Prieto M, Lopez-Novoa J, Lopez-Hernandez F . Subcellular targets of cisplatin cytotoxicity: an integrated view. Pharmacol Ther. 2012; 136(1):35-55. DOI: 10.1016/j.pharmthera.2012.07.003. View

16.

Gu Y, Fan S, Xiong Y, Peng B, Zheng G, Yu Y . Cloning and functional characterization of TCRP1, a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line. FEBS Lett. 2011; 585(6):881-7. DOI: 10.1016/j.febslet.2010.12.045. View

17.

Liotta L, Kohn E . The microenvironment of the tumour-host interface. Nature. 2001; 411(6835):375-9. DOI: 10.1038/35077241. View

18.

Wang F, Ji X, Wang J, Ma X, Yang Y, Zuo J . LncRNA PVT1 Enhances Proliferation and Cisplatin Resistance via Regulating miR-194-5p/HIF1a Axis in Oral Squamous Cell Carcinoma. Onco Targets Ther. 2020; 13:243-252. PMC: 6957095. DOI: 10.2147/OTT.S232405. View

19.

Qi X, Xu W, Xie J, Wang Y, Han S, Wei Z . Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis. Sci Rep. 2016; 6:35788. PMC: 5071902. DOI: 10.1038/srep35788. View

20.

Gharat S, Momin M, Bhavsar C . Oral Squamous Cell Carcinoma: Current Treatment Strategies and Nanotechnology-Based Approaches for Prevention and Therapy. Crit Rev Ther Drug Carrier Syst. 2016; 33(4):363-400. DOI: 10.1615/CritRevTherDrugCarrierSyst.2016016272. View